Background
==========

COPD is a chronic disease of the lungs and is characterized by irreversible airflow limitation, and is currently the third leading cause of death in the United States \[[@B1]-[@B3]\]. GOLD defines COPD as a preventable and treatable disease with airflow limitation that is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases \[[@B4]\]. Both the American Thoracic Society (ATS) and the European Respiratory Society (ERS) have, in large part, adopted this definition \[[@B5]\].

Response to a bronchodilator is thought to be important in COPD diagnosis and guidelines suggest that classification of COPD be made using spirometry performed after bronchodilator administration \[[@B4]\]. While asthma generally has more reversibility to a bronchodilator than COPD, the presence of reversibility does not distinguish asthma from COPD \[[@B6]\].

According to the 2008 GOLD guidelines \"Spirometry should be performed after the administration of an adequate dose of an inhaled bronchodilator (e.g., 400 μg salbutamol) \[[@B7]\] in order to minimize variability. In a random population study to determine spirometry reference values, post-bronchodilator values differed from pre-bronchodilator values \[[@B8]\]. Furthermore, post-bronchodilator lung function testing in a community setting has been demonstrated to be an effective method to identify individuals with COPD \[[@B9],[@B10]\]. However, most longitudinal studies looking at the effect of impaired lung function on outcomes such as mortality and hospitalizations have used pre-bronchodilator lung function \[[@B11]-[@B14]\].

The purpose of this study is to determine whether pre- or post-bronchodilator lung function differentially predict mortality in cohorts over time. Data from the Lung Health Study \[[@B15]\] was used in this analysis.

Methods
=======

The Lung Health Study (LHS) was a randomized multicenter clinical trial that was carried out from October 1986 through April 1994 \[[@B15],[@B16]\]. A detailed description of the LHS design has been previously published \[[@B16]\]. Briefly, \"healthy\" current smokers between the ages of 35 and 60 were enrolled if their forced expiratory volume in one second (FEV~1~) to forced vital capacity (FVC) was less than 70% and their FEV~1~was between 55% and 90% of the predicted normal value. Subjects were randomized into three groups: a control group receiving \"usual care\", a smoking intervention group receiving placebo, and a smoking intervention group receiving the bronchodilator ipratroprium. Lung function was measured before and after two inhalations (200-μg total dose) of isoproteronol from a metered-dose inhaler.

We used data from the year 1(one year following baseline) and year 5 (5 years following baseline) visits and included subjects who had complete data and both pre- and post-bronchodilator lung function measurements at these visits. The rationale for using these visits was that the inclusion criteria limited the range of lung disease severity at baseline to mild and moderate COPD, whereas a broader range could be seen in subsequent visits. In addition, prior work has demonstrated that bronchodilator responsiveness was larger in year 1 and subsequent years than it was at baseline \[[@B17]\].

About 75% of the original cohort of 5887 participants were followed continuously for 10 years beyond the 5-year time frame of Lung Health Study I (these subjects were mostly participants in Lung Health Study III) by biannual phone contacts (to ascertain vital status, smoking status, morbidity and mortality). Our primary endpoint was all-cause mortality at up to 14.5 years of follow-up from baseline \[[@B18]\]. The time metric used was time from the year 1 examination to the time of death or the end of the study or from the year 5 examination to the end of the study.

Study Measures
--------------

Predicted values from the Third National Health and Nutrition Examination Survey (NHANES III) were used in the analysis \[[@B19]\]. We used age, sex, height and race to determine the predicted values. The study participants were classified, using the pre- and post-bronchodilator lung function, into five lung function categories based on a modification of COPD classification criteria: Normal (no airflow obstruction or restriction), restricted (FEV~1~/FVC ≥ 70% and FVC \< 80% of predicted), Stage 1 (FEV~1~/FVC \< 70% and FEV~1~≥ 80% predicted), Stage 2 (FEV~1~/FVC \< 70% and 50% ≤ FEV~1~\< 80% predicted), and Stage 3 or 4 (FEV~1~/FVC \< 70% and FEV~1~\< 50% predicted) \[[@B4]\].

Definitions
-----------

Demographic data included in this analysis were sex, age, body mass index (BMI), smoking status, race, and educational status. Age was classified at baseline, the year 1, and year 5 examinations and was categorized for use in tables (35-39, 40-49, 50-50, and 60 and older), and was used as a continuous variable in the survival analyses. BMI was categorized at baseline and was categorized into 3 categories (\< 25, 25-29, and \> = 30 kg/m^2^), and was used as a continuous variable in the survival analyses. All subjects were smokers at baseline, so smoking status was classified based on their second through fifth follow-up visits as current smokers for those who never stopped smoking, former smokers for those who successfully quit, and intermittent smokers for those whose status varied \[[@B20]\]. Education status was stratified into three levels (\< 12 years, 12 years, and \> 12 years). Race was classified as White or Black, with people of other races excluded. The original design of the study was incorporated by stratifying the subjects by randomization group: Intervention with ipratroprium, Intervention with placebo, and Control.

Statistical Analysis
--------------------

Data analysis was completed using statistical software (Statistical Analysis Software, version 9.2; SAS Institute; Cary, NC and SUDAAN version 10.1; RTI, Research Triangle Park, NC). Our primary outcome of interest in the survival models was mortality, and the main predictor of interest in our analysis was COPD severity defined by stage of lung function, both pre- and post-bronchodilator, and a separate analysis using FEV~1~as a percent of predicted, both pre- and post-bronchodilator. We calculated the deaths per 1,000 person years of follow-up for our key covariates. Cox proportional hazard regression models were developed using the SUDAAN procedure SURVIVAL to account for differential follow up in cohort participants. Time of follow up was used as the underlying time metric. Censoring occurred at the date of death certificate or date the participant was last known to be alive. Plots of the log-log survival curves for each covariate were produced to evaluate the proportional hazards assumptions. Age, sex, race, smoking status, education level, body mass index and randomization cohort were included in the adjusted models.

Results
=======

There were a total of 5,887 participants in the Lung Health Study, of whom 721 died by the end of the follow-up period of up to 15 years. The major causes of death at follow-up were lung cancer and cardiovascular disease with comparatively fewer deaths due to non-malignant respiratory disease. At baseline, the mean age of the cohort was 48.5 years and the mean FEV~1~was 74.7%. Of these, we had complete data on 5,307 who participated in the examination at year 1 (there were 13 deaths before the year 1 visit). Among the 5,307 on whom we had complete data at year 1, we had 65,472 person years of follow-up, with a median and maximum follow-up time of 12.8 and 14.0 years, and 628 deaths (Table [1](#T1){ref-type="table"}). Among the 5,320 on whom we had complete data at year 5 (there were 149 deaths prior to the year 5 visit), we had 45,808 person years of follow-up, with a median and maximum follow-up time of 8.8 and 10.0 years, and 500 deaths (Table [2](#T2){ref-type="table"}).

###### 

Characteristics of Analyzed Population at Year 1 (n = 5,307) with 628 deaths at up to 15 years of follow-up

                                  N      \%     Person-Years of Follow-up   Deaths per 1,000 Person Years
  ------------------------------- ------ ------ --------------------------- -------------------------------
  Sex                                                                       
   Female                         1993   37.6   24,764                      8.3
   Male                           3314   62.4   40,708                      10.4
  Age Group, Years                                                          
   35-39                          522    9.8    6,610                       3.8
   40-49                          2099   39.6   26,350                      5.5
   50-59                          2494   47.0   30,267                      13.7
   60+                            192    3.6    2,245                       18.7
  Body Mass Index, kg/m^2^                                                  
   \< 25                          2528   47.6   31,168                      9.5
   25- 30                         2082   39.2   25,791                      9.1
   \> = 30                        697    13.1   8,513                       11.5
  Education, Years                                                          
   \< 12                          632    11.9   7,720                       13.0
   12                             1592   30.0   19,629                      10.0
   \> 12                          3083   58.1   38,123                      8.7
  Race                                                                      
   White                          5108   96.3   63,117                      9.2
   Black                          199    3.7    2,355                       20.8
  Smoking Status                                                            
   Former                         1439   27.1   17,966                      7.0
   Intermittent                   628    11.8   7,752                       9.5
   Current                        3240   61.1   39,754                      10.8
  Randomization Group                                                       
   Intervention, Ipratroprium     1793   33.8   22,141                      8.9
   Intervention, Placebo          1785   33.6   22,108                      9.0
   Control                        1729   32.6   21,223                      11.0
  Stage (pre-bronchodilator)\*                                              
   Stage 3 or 4                   67     1.3    799                         15.0
   Stage 2                        3432   64.7   42,208                      10.7
   Stage 1                        1354   25.5   16,852                      7.3
   Restricted                     69     1.3    840                         9.5
   Normal                         385    7.3    4,773                       6.7
  Stage (post-bronchodilator)\*                                             
   Stage 3 or 4                   19     0.4    224                         13.4
   Stage 2                        2540   47.9   31,126                      12.1
   Stage 1                        1565   29.5   19,386                      7.8
   Restricted                     125    2.4    1,487                       12.1
   Normal                         1058   19.9   13,249                      5.8

\*Modified chronic obstructive pulmonary disease stage, as defined in methods

###### 

Characteristics of Analyzed Population at Year 5 (n = 5,320) with 500 deaths at up to 10 years of follow-up

                                  N       \%     Person-Years of Follow-up   Deaths per 1,000 Person Years
  ------------------------------- ------- ------ --------------------------- -------------------------------
  Sex                                                                        
   Female                         1,992   37.4   17,221                      9.4
   Male                           3,328   62.6   28,587                      11.8
  Age Group, years                                                           
   35-39                          25      0.5    214                         9.3
   40-49                          1,708   32.1   14,995                      4.7
   50-59                          2,436   45.8   20,954                      11.4
   60+                            1,151   21.6   9,644                       19.7
  Body Mass Index, kg/m2                                                     
   \< 25                          2,536   47.7   21,849                      10.7
   25- 30                         2,098   39.4   18,075                      10.6
   \> = 30                        686     12.9   5,884                       12.7
  Education (years)                                                          
   \< 12                          639     12.0   5,496                       14.0
   12                             1,595   30.0   13,735                      11.5
   \> 12                          3,086   58.0   26,577                      10.0
  Race                                                                       
   White                          5,136   96.5   44,226                      10.6
   Non-White                      184     3.5    1,582                       19.6
  Smoking Status                                                             
   Former                         1,386   26.1   12,063                      7.5
   Intermittent                   627     11.8   5,403                       10.2
   Current                        3,307   62.2   28,342                      12.5
  Randomization Group                                                        
   Intervention, Ipratroprium     1,791   33.7   15,470                      9.6
   Intervention, Placebo          1,770   33.3   15,271                      10.5
   Control                        1,759   33.1   15,067                      12.7
  Stage (pre-bronchodilator)\*                                               
   Stage 3 or 4                   341     6.4    2,831                       21.5
   Stage 2                        3,587   67.4   30,875                      11.3
   Stage 1                        995     18.7   8,674                       7.3
   Restricted                     92      1.7    768                         15.6
   Normal                         305     5.7    2,659                       5.6
  Stage (post-bronchodilator)\*                                              
   Stage 3 or 4                   183     3.4    1,475                       29.8
   Stage 2                        3,048   57.3   26,237                      12.0
   Stage 1                        1,242   23.3   10,775                      7.2
   Restricted                     126     2.4    1,059                       13.2
   Normal                         721     13.6   6,262                       7.8

\*Modified chronic obstructive pulmonary disease stage, as defined in methods

Table [1](#T1){ref-type="table"} provides additional detail on the covariates of the cohort at year 1, including the total follow-up time and the mortality rate per 1,000 person-years of follow-up. As would be expected, age was the strongest predictor of mortality. Similar data for the Year 5 cohort is displayed in Table [2](#T2){ref-type="table"}.

Changes in the COPD classification stages between pre- and post-bronchodilator lung function measurements for the year 1 and the year cohort is shown in Table [3](#T3){ref-type="table"}. At year 1, 3,804 of 5,307 (71.7%) remained in the same category for both pre- and post-bronchodilator FEV~1~and at year 5, 4,079 of 5,320 (76.7%) remained in the same category for both pre- and post-bronchodilator FEV~1~. The mean FEV~1~, as a percentage of predicted, increased from 74.1% (Standard deviation \[SD\] 10.3%) to78.1% (SD 10.0%) at year 1 and from 70.3% (SD 12.5%) to 74.3% (SD 12.1%) at year 5.

###### 

Comparison of pre- and post-bronchodilator classifications from Year 1 and Year 5 visits

  Year 1               Post-Bronchodilator                                                         
  -------------------- --------------------- --------------------- --------- ------------ -------- -------
  Stage 3 or 4\*       17                    50                    0         0            0        67
  Stage 2              1                     2442                  578       76           335      3432
  Stage 1              0                     28                    959       0            367      1354
  Restricted           1                     10                    0         44           14       69
  Normal               0                     10                    28        5            342      385
  Total                19                    2540                  1565      125          1058     5307
  Year 5                                                                                           
                                             Post-Bronchodilator                                   
  Pre-Bronchodilator   Stage 3 or 4\*        Stage 2               Stage 1   Restricted   Normal   Total
  Stage 3 or 4\*       172                   168                   0         1            0        341
  Stage 2              10                    2823                  482       67           205      3587
  Stage 1              0                     27                    748       0            220      995
  Restricted           1                     18                    1         56           16       92
  Normal               0                     12                    11        2            280      305
  Total                183                   3048                  1242      126          721      5320

The rows represent the pre-bronchodilator values and the columns represent the post-bronchodilator values (i.e. at year one 67/5307 were stage 3 or 4 pre- and 19/5307 were stage 3 or 4 post-bronchodilator). Year 1 Post-Bronchodilator

\*Modified chronic obstructive pulmonary disease stage, as defined in methods

The Cox proportional hazards models for the year 1 cohort are shown in Table [4](#T4){ref-type="table"}. Age, sex, education level, race, and smoking status were significant predictors of mortality, but in these models COPD classification stage reached statistical significance in only stage 2 of the post-bronchodilator model. The area under the curve, from the PROC logistic model, was 69.2% for the pre- and 69.6% for the post- bronchodilator model. In parallel models that used pre- and post-bronchodilator FEV~1~, as a percentage of predicted, a higher FEV~1~% predicted lower mortality in both the pre- (HR 0.87, 95% CI 0.81, 0.94 per 10% increase) and post-bronchodilator (HR 0.84, 95% CI 0.77, 0.90) models. The area under the curve for the respective models was 69.2% and 69.4%.

###### 

Results from Cox Proportional hazards survival models on year 1 sample- Mortality follow-up of up to 15 years

                                  Hazards Ratio   95% Confidence Interval
  ------------------------------- --------------- -------------------------
  Sex                                             
   Male                           1.34            (1.12, 1.59)
   Female                         1.00            
  Age                             1.09            (1.07, 1.10)
  Body Mass Index                 1.00            (0.98, 1.03)
  Education                                       
   \< 12 Years                    1.29            (1.03, 1.61)
   12 Years                       1.08            (0.90, 1.29)
   \> 12 Years                    1.00            
  Race                                            
   White                          1.00            
   Black                          2.13            (1.57, 2.88)
  Smoking Status                                  
   Former Smoker                  0.64            (0.52, 0.79)
   Intermittent Smoker            0.89            (0.69, 1.15)
   Current Smoker                 1.00            
  Randomization Group                             
   Intervention, Ipratroprium     0.92            (0.76, 1.12)
   Intervention, Placebo          0.89            (0.74, 1.09)
   Control                        1.00            
  Stage (Pre-bronchodilator)\*                    
   Stage 3 or 4                   1.51            (0.75, 3.03)
   Stage 2                        1.36            (0.95, 1.95)
   Stage 1                        0.97            (0.65, 1.44)
   Restricted                     1.12            (0.51, 2.48)
   Normal                         1.00            
                                                  
  Stage (Post-bronchodilator)\*                   
   Stage 3 or 4                   1.45            (0.41, 5.15)
   Stage 2                        1.54            (1.20, 1.98)
   Stage 1                        1.06            (0.80, 1.40)
   Restricted                     1.63            (0.96, 2.75)
   Normal                         1.00            

Results for post-bronchodilator lung function measurement is displayed without showing results for the other covariates.

\*Modified chronic obstructive pulmonary disease stage, as defined in methods

Similar models for the year 5 follow-up data are shown in Table [5](#T5){ref-type="table"}. The main difference seen between the year 1 and year 5 models is that the latter now show an increased risk of Stage 3 or 4 COPD on mortality in both the pre- (HR 2.68, 95% CI 1.51, 4.75) and post-bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models. The area under the curve was 69.0% for the pre- and 69.5% for the post-bronchodilator models. Similar models using FEV~1~showed that a higher FEV~1~% predicted lower mortality in both the pre-bronchodilator (HR 0.84, 95% CI 0.75, 0.87 per 10% increase) and post-bronchodilator (HR 0.78, 95% CI 0.73, 0.90) models. The area under the curve for the respective models was 69.4% and 69.8%.

###### 

Results from Year 5 sample, mortality follow-up of up to 10 years

                                  Hazards Ratio   95% Confidence Interval
  ------------------------------- --------------- -------------------------
  Sex                                             
   Male                           1.36            (1.12, 1.64)
   Female                         1.00            
  Age                             1.09            (1.07, 1.10)
  Body Mass Index                 1.01            (0.98, 1.03)
  Education                                       
   \< 12 Years                    1.24            (0.96, 1.59)
   12 Years                       1.10            (0.90, 1.34)
   \> 12 Years                    1.00            
  Race                                            
   White                          1.00            
   Black                          1.77            (1.22, 2.56)
  Smoking Status                                  
   Former Smoker                  0.63            (0.50, 0.80)
   Intermittent Smoker            0.85            (0.64, 1.13)
   Current Smoker                 1.00            
  Randomization Group                             
   Intervention, Ipratroprium     0.86            (0.69, 1.07)
   Intervention, Placebo          0.91            (0.74, 1.13)
   Control                        1.00            
  Stage (Pre-bronchodilator)\*                    
   Stage 3 or 4                   2.68            (1.51, 4.75)
   Stage 2                        1.60            (0.94, 2.69)
   Stage 1                        1.12            (0.63, 1.98)
   Restricted                     2.25            (1.04, 4.86)
   Normal                         1.00            
                                                  
  Stage (Post-bronchodilator)\*                   
   Stage 3 or 4                   2.46            (1.63, 3.73)
   Stage 2                        1.11            (0.82, 1.51)
   Stage 1                        0.74            (0.52, 1.06)
   Restricted                     1.36            (0.74, 2.47)
   Normal                         1.00            

\*Modified chronic obstructive pulmonary disease stage, as defined in methods

Discussion
==========

This analysis examined data from the Lung Health Study to determine whether post-bronchodilator lung function predicts mortality. Overall, we found that the pre- and post-bronchodilator measures of lung function, whether used categorically (as stages of COPD) or continuously (as FEV~1~% predicted) predicted mortality similarly. This finding suggests that post-bronchodilator lung function data may not be needed for studies that look at long term outcomes in COPD.

Most guidelines defining COPD say that spirometry should be performed after the administration of an adequate dose of an inhaled bronchodilator in order to minimize variability \[[@B4],[@B21]\]. These same guidelines, however, state that \"neither bronchodilator nor oral glucocorticosteroid reversibility testing predicts disease progression, whether judged by decline in FEV~1~, deterioration of health status, or frequency of exacerbations in patients with a clinical diagnosis of COPD and abnormal spirometry. Small changes in FEV~1~(e.g., \< 400 ml) after administration of a bronchodilator do not reliably predict the patient\'s response to treatment\" \[[@B4]\]. Others have suggested that one cannot use prebronchodilator lung function to define COPD, the reason being that airflow limitation can be variable and that this component can be easily reverse with a bronchodilator \[[@B22]\]. Other research, though, has suggested that bronchodilator responsiveness is highly variable and that \"over half the patients initially classified as reversible by the ATS/GOLD definition would be reclassified had they attended on another occasion\" \[[@B23]\].

In population-based studies, one would expect that post-bronchodilator lung function measurement would reduce the prevalence of COPD. For example, in the PLATINO study, bronchodilator testing reduced the overall prevalence of FEV~1~/FVC% \< 0.70 from 21.7% to 14% \[[@B24]\]. In our analysis the prevalence of severe COPD was lower in the post- compared to the pre-bronchodilator lung function in both the year 1 (0.4% vs. 1.3%) and the year 5 (3.4% vs. 6.4%) cohorts. The finding of a lower prevalence, however, does not necessarily mean that this is the correct prevalence.

Others have looked at this problem in different ways. For example, Hansen et al studied 985 patients with COPD and found that the response to a bronchodilator was a positive prognostic factor along with FEV~1~at baseline. However, if baseline FEV~1~was substituted with post-bronchodilator FEV~1~, the bronchodilator reversibility became nonsignificant \[[@B25]\]. Compared to our population, that population had much lower lung function (mean FEV~1~38.5% of predicted compared to our mean FEV~1~of 74.7%) and was much older (mean age 61.8 years at baseline compared to our mean age of 48.5 years). Still, the predictive value for FEV~1~in their study was similar in the pre- (relative risk \[RR\] 0.60, 95% CI 0.54, 0.81) and post- bronchodilator (RR 0.62, 95% CI 0.56, 0.69) models.

Burrows acknowledged the complexity of the relation between bronchodilator responsiveness and outcomes in obstructive lung disease \[[@B26]\]. He noted that different studies had varying results \[[@B27],[@B28]\] and suggested that several factors, such as how baseline lung function is determined, how responsiveness is measured, and the prevalence of \"asthma\" in the studied population, may be important determinants of outcomes. His conclusion that mortality is \"related to age and to a low initial post-bronchodilator FEV~1~\" provides, in part, the historic rationale for using post-bronchodilator lung function to define COPD.

This study has limitations that are important to its interpretation. The most important was that it was not a true \"population-based\" study but was a clinical intervention trial that targeted early COPD. Study participants had to be current smokers at entry with lung function that was mildly abnormal, and subjects who regularly used bronchodilators were excluded. Although asthma history was not a specific exclusion criterion, excluding people with regular bronchodilator use had the net effect of eliminating subjects with clinically significant asthma from the population. Thus, these findings may not necessarily apply to a population that includes never smokers or where a large proportion of the population has asthma that is symptomatic. Also, a more inclusive population of smokers where reversibility is more common may have yielded different results. This limitation is decreased by our study design that looked at data from the year 1 and year 5 follow-up, at which point some subjects had stopped smoking and many developed symptoms consistent with asthma or COPD. In addition, one would not expect the post-bronchodilator FEV~1~of never smokers (in the absence of asthma) to differ significantly from the pre-bronchodilator value. Finally, the dose of bronchodilator used in this study (two inhalations, 200-μg total dose, of isoproterenol) is less than what has been used in other clinical trials, some of which have used 400 μg of isoproterenol and 400 μg of albuterol \[[@B29]\]. Thus, it is unknown whether the findings would be similar if a \"maximal bronchodilitation\" protocol was used.

Another limitation was the absence of other important measures of COPD, such as an impaired exercise testing, impaired diffusion capacity or abnormal imaging. Recent work \[[@B30]-[@B32]\] in COPD has highlighted that measures other than lung function are important predictors of impaired function and poor outcomes. Lung function remains, however, the primary means of diagnosing and classifying COPD at the present time and this is unlikely to change in the foreseeable future.

Conclusion
==========

We found that is this cohort both pre- and post-bronchodilator lung function predicted mortality with similar accuracy. This validates the approach taken in a number of long-term studies where only prebronchodilator lung function is available, although studies that include similar data in never smokers and subjects with asthma are needed.
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